Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Clinigen building global leader, says Peel Hunt

Clinigen is building a global leader in its chosen markets and is set for a stronger performance in the second half, says house broker Peel Hunt, which rates shares a 'buy'. .
Clinigen building global leader, says Peel Hunt
"Clinigen is the leading player in its key markets of supply and management of clinical trials, access to medicines for patients with unmet needs and ethical unlicensed supply market," said analyst Charles Hall.

Clinigen (LON:CLIN) is building a global leader in its chosen markets and is set for a stronger performance in the second half, says house broker Peel Hunt, which rates shares a 'buy'.

Its note comes after the recent first half trading update,  which saw revenues and gross profit advance 116% and 100% respectively - mainly boosted by acquisitions.

"Clinigen is the leading player in its key markets of supply and management of clinical trials, access to medicines for patients with unmet needs and ethical unlicensed supply market," said analyst Charles Hall.

Overall these markets are estimated to be worth around US$5.3bn, he noted,  which compares to Clinigen’s 2016 forecast sales of approximately $500mln, giving  the firm a share of around 10%.

Last spring's purchase of Idis, a specialist in the ethical supply on unlicensed medicines, and Link Healthcare, which has become part of Clinigen’s managed access division, have been 'transformational' for the firm, along with the global alliance  with NASDAQ-listed Cumberland Pharmaceuticals, and the benefits will increasingly be apparent in the second half.

For example, Link provides access to markets in Africa, Asia and Australasia, the broker noted.

Hall says he expects the firm to deliver £24mln of free cash flow in the current year rising to £44mln in 2017, which compares to the broker's year end net debt forecast of £78mln.

"The focus in the short term is to integrate the recent acquisitions and pay down debt, but this gives significant firepower to make further acquisitions out of free cash flow," added the analyst.

Peel Hunt targets 1,000p for the shares - a significant distance from where they are now at around 632p

Giles_55af4ddca6481.jpg
Why Invest In Clinigen Group PLC? Read More Here

Register here to be notified of future CLIN Company articles
View full CLIN profile

Clinigen Group PLC Timeline

Newswire
November 11 2016
Newswire
October 25 2016
Article
October 18 2016
Article
September 28 2016

Related Articles

A graphic of a tumour growing in the body
July 07 2016
Nanobiotix is a late clinical-stage nanomedicine company researching novel approaches to enhance radiotherapy for the local treatment of cancer.
Magnified view of cancer cells
July 28 2016
ANGLE's Parsortix blood screening system could replace the traditional biopsy in the diagnosis of breast cancer. Proactive takes a look at how it works and the potential it holds to change the way cancer is diagnosed.
shutterstock_234586750.jpg
Wed
N+1, in a note to clients, described the financial performance as “solid”, which perhaps understated Abzena’s progress in the six months to September 30.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.